|
|
Previous Article | Table of Contents | Next Article 
Blood, 15 December 2000, Vol. 96, No. 13, pp. 4212-4215
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Plasminogen activator inhibitor-1 deficiency protects against
atherosclerosis progression in the mouse carotid artery
Daniel T. Eitzman,
Randal
J. Westrick,
Zuojun Xu,
Julia Tyson, and
David Ginsburg
From the Divisions of Cardiology and Medical Genetics,
Department of Internal Medicine, and the Howard Hughes Medical
Institute, University of Michigan Medical Center, Ann Arbor, MI.
Dissolution of the fibrin blood clot is regulated in large part by
plasminogen activator inhibitor-1 (PAI-1). Elevated levels of plasma
PAI-1 may be an important risk factor for atherosclerotic vascular
disease and are associated with premature myocardial infarction. The
role of the endogenous plasminogen activation system in limiting
thrombus formation following atherosclerotic plaque disruption is
unknown. This study found that genetic deficiency for PAI-1, the
primary physiologic regulator of tissue-type plasminogen activator
(tPA), prolonged the time to occlusive thrombosis following photochemical injury to carotid atherosclerotic plaque in
apolipoprotein E-deficient (apoE / ) mice. However,
anatomic analysis revealed a striking difference in the extent of
atherosclerosis at the carotid artery bifurcation between
apoE / mice and mice doubly deficient for apoE and PAI-1
(PAI-1 / /apoE / ). Consistent with a
previous report, PAI-1+/+/apoE / and
PAI-1 / /apoE / mice developed similar
atherosclerosis in the aortic arch. The marked protection from
atherosclerosis progression at the carotid bifurcation conferred by
PAI-1 deficiency suggests a critical role for PAI-1 in the pathogenesis
of atherosclerosis at sites of turbulent flow, potentially through the
inhibition of fibrin clearance. Consistent with this hypothesis,
intense fibrinogen/fibrin staining was observed in atherosclerotic
lesions at the carotid bifurcation compared to the aortic arch. These
observations identify significant differences in the pathogenesis of
atherosclerosis at varying sites in the vascular tree and suggest a
previously unappreciated role for the plasminogen activation system in
atherosclerosis progression at sites of turbulent flow.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
G. G. Camici, J. Steffel, I. Amanovic, A. Breitenstein, J. Baldinger, S. Keller, T. F. Luscher, and F. C. Tanner
Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents
Eur. Heart J.,
June 29, 2009;
(2009)
ehp259v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Peters, M. Kastantin, V. R. Kotamraju, P. P. Karmali, K. Gujraty, M. Tirrell, and E. Ruoslahti
Targeting atherosclerosis by using modular, multifunctional micelles
PNAS,
June 16, 2009;
106(24):
9815 - 9819.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Liu, A. E Dear, L. B Knudsen, and R. W Simpson
A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules
J. Endocrinol.,
April 1, 2009;
201(1):
59 - 66.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Drinane, J. Mollmark, L. Zagorchev, K. Moodie, B. Sun, A. Hall, S. Shipman, P. Morganelli, M. Simons, and M. J. Mulligan-Kehoe
The Antiangiogenic Activity of rPAI-123 Inhibits Vasa Vasorum and Growth of Atherosclerotic Plaque
Circ. Res.,
February 13, 2009;
104(3):
337 - 345.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. C. Werneck, C. P. Vicente, J. S. Weinberg, A. Shifren, R. A. Pierce, T. J. Broekelmann, D. M. Tollefsen, and R. P. Mecham
Mice lacking the extracellular matrix protein MAGP1 display delayed thrombotic occlusion following vessel injury
Blood,
April 15, 2008;
111(8):
4137 - 4144.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Izuhara, S. Takahashi, M. Nangaku, S. Takizawa, H. Ishida, K. Kurokawa, C. van Ypersele de Strihou, N. Hirayama, and T. Miyata
Inhibition of Plasminogen Activator Inhibitor-1: Its Mechanism and Effectiveness on Coagulation and Fibrosis
Arterioscler. Thromb. Vasc. Biol.,
April 1, 2008;
28(4):
672 - 677.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. L.C. Hoo, W.S. Chow, M.H. Yau, A. Xu, A. W.K. Tso, H.F. Tse, C. H.Y. Fong, S. Tam, L. Chan, and K. S.L. Lam
Adiponectin Mediates the Suppressive Effect of Rosiglitazone on Plasminogen Activator Inhibitor-1 Production
Arterioscler. Thromb. Vasc. Biol.,
December 1, 2007;
27(12):
2777 - 2782.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Westrick, M. E. Winn, and D. T. Eitzman
Murine Models of Vascular Thrombosis
Arterioscler. Thromb. Vasc. Biol.,
October 1, 2007;
27(10):
2079 - 2093.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Thalmann and C. A. Meier
Local adipose tissue depots as cardiovascular risk factors
Cardiovasc Res,
September 1, 2007;
75(4):
690 - 701.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. P. Fay, N. Garg, and M. Sunkar
Vascular Functions of the Plasminogen Activation System
Arterioscler. Thromb. Vasc. Biol.,
June 1, 2007;
27(6):
1231 - 1237.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Hu, L.S.M. Boesten, P. May, J. Herz, N. Bovenschen, M.V. Huisman, J.F.P. Berbee, L.M. Havekes, B.J.M. van Vlijmen, and J.T. Tamsma
Macrophage Low-Density Lipoprotein Receptor-Related Protein Deficiency Enhances Atherosclerosis in ApoE/LDLR Double Knockout Mice
Arterioscler. Thromb. Vasc. Biol.,
December 1, 2006;
26(12):
2710 - 2715.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Wang, L. Yin, and M. A. Lazar
The Orphan Nuclear Receptor Rev-erb{alpha} Regulates Circadian Expression of Plasminogen Activator Inhibitor Type 1
J. Biol. Chem.,
November 10, 2006;
281(45):
33842 - 33848.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. G. Camici, J. Steffel, A. Akhmedov, N. Schafer, J. Baldinger, U. Schulz, K. Shojaati, C. M. Matter, Z. Yang, T. F. Luscher, et al.
Dimethyl Sulfoxide Inhibits Tissue Factor Expression, Thrombus Formation, and Vascular Smooth Muscle Cell Activation: A Potential Treatment Strategy for Drug-Eluting Stents
Circulation,
October 3, 2006;
114(14):
1512 - 1521.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. K. Hennan, H. Elokdah, M. Leal, A. Ji, G. S. Friedrichs, G. A. Morgan, R. E. Swillo, T. M. Antrilli, A. Hreha, and D. L. Crandall
Evaluation of PAI-039 [{1-Benzyl-5-[4-(trifluoromethoxy)phenyl]-1H-indol-3-yl}(oxo)acetic Acid], a Novel Plasminogen Activator Inhibitor-1 Inhibitor, in a Canine Model of Coronary Artery Thrombosis
J. Pharmacol. Exp. Ther.,
August 1, 2005;
314(2):
710 - 716.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Yamamoto, K. Takeshita, T. Kojima, J. Takamatsu, and H. Saito
Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly
Cardiovasc Res,
May 1, 2005;
66(2):
276 - 285.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. T. Eitzman, R. J. Westrick, Y. Shen, P. F. Bodary, S. Gu, S. L. Manning, S. L. Dobies, and D. Ginsburg
Homozygosity for Factor V Leiden Leads to Enhanced Thrombosis and Atherosclerosis in Mice
Circulation,
April 12, 2005;
111(14):
1822 - 1825.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C Roncal, J Orbe, J.A Rodriguez, M Belzunce, O Beloqui, J Diez, and J.A Paramo
Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension
Cardiovasc Res,
July 1, 2004;
63(1):
176 - 185.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. S. Espirito Santo, N. M. M. Pires, L. S. M. Boesten, G. Gerritsen, N. Bovenschen, K. W. van Dijk, J. W. Jukema, H. M. G. Princen, A. Bensadoun, W.-P. Li, et al.
Hepatic low-density lipoprotein receptor-related protein deficiency in mice increases atherosclerosis independent of plasma cholesterol
Blood,
May 15, 2004;
103(10):
3777 - 3782.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. E. Cozen, H. Moriwaki, M. Kremen, M. B. DeYoung, H. L. Dichek, K. I. Slezicki, S. G. Young, M. Veniant, and D. A. Dichek
Macrophage-Targeted Overexpression of Urokinase Causes Accelerated Atherosclerosis, Coronary Artery Occlusions, and Premature Death
Circulation,
May 4, 2004;
109(17):
2129 - 2135.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Xu, R. D. Balsara, N. V. Gorlatova, D. A. Lawrence, F. J. Castellino, and V. A. Ploplis
Conservation of Critical Functional Domains in Murine Plasminogen Activator Inhibitor-1
J. Biol. Chem.,
April 23, 2004;
279(17):
17914 - 17920.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Ishimori, R. Li, P. M. Kelmenson, R. Korstanje, K. A. Walsh, G. A. Churchill, K. Forsman-Semb, and B. Paigen
Quantitative Trait Loci Analysis for Plasma HDL-Cholesterol Concentrations and Atherosclerosis Susceptibility Between Inbred Mouse Strains C57BL/6J and 129S1/SvImJ
Arterioscler. Thromb. Vasc. Biol.,
January 1, 2004;
24(1):
161 - 166.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Roest and J. D. Banga
Editorial Comment-- Genetic Make-Up for Increased PAI-1 Expression Protects Against Stroke
Stroke,
December 1, 2003;
34(12):
2828 - 2829.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. E. Sobel, D. J. Taatjes, and D. J. Schneider
Intramural Plasminogen Activator Inhibitor Type-1 and Coronary Atherosclerosis
Arterioscler. Thromb. Vasc. Biol.,
November 1, 2003;
23(11):
1979 - 1989.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Schafer, K. Muller, A. Hecke, E. Mounier, J. Goebel, D. J. Loskutoff, and S. Konstantinides
Enhanced Thrombosis in Atherosclerosis-Prone Mice Is Associated With Increased Arterial Expression of Plasminogen Activator Inhibitor-1
Arterioscler. Thromb. Vasc. Biol.,
November 1, 2003;
23(11):
2097 - 2103.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Bot, J. H. von der Thusen, M. M.P.C. Donners, A. Lucas, M. L. Fekkes, S. C.A. de Jager, J. Kuiper, M. J.A.P. Daemen, T. J.C. van Berkel, S. Heeneman, et al.
Serine Protease Inhibitor Serp-1 Strongly Impairs Atherosclerotic Lesion Formation and Induces a Stable Plaque Phenotype in ApoE-/- Mice
Circ. Res.,
September 5, 2003;
93(5):
464 - 471.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-C. Alessi, D. Bastelica, A. Mavri, P. Morange, B. Berthet, M. Grino, and I. Juhan-Vague
Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue Accumulation
Arterioscler. Thromb. Vasc. Biol.,
July 1, 2003;
23(7):
1262 - 1268.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. J. Lyon, R. E. Law, and W. A. Hsueh
Minireview: Adiposity, Inflammation, and Atherogenesis
Endocrinology,
June 1, 2003;
144(6):
2195 - 2200.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. V. Gorlatova, H. Elokdah, K. Fan, D. L. Crandall, and D. A. Lawrence
Mapping of a Conformational Epitope on Plasminogen Activator Inhibitor-1 by Random Mutagenesis. IMPLICATIONS FOR SERPIN FUNCTION
J. Biol. Chem.,
April 25, 2003;
278(18):
16329 - 16335.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. T. Askari, M.-L. Brennan, X. Zhou, J. Drinko, A. Morehead, J. D. Thomas, E. J. Topol, S. L. Hazen, and M. S. Penn
Myeloperoxidase and Plasminogen Activator Inhibitor 1 Play a Central Role in Ventricular Remodeling after Myocardial Infarction
J. Exp. Med.,
March 3, 2003;
197(5):
615 - 624.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Devaraj, D. Y. Xu, and I. Jialal
C-Reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression and Activity in Human Aortic Endothelial Cells: Implications for the Metabolic Syndrome and Atherothrombosis
Circulation,
January 28, 2003;
107(3):
398 - 404.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. de Waard, E. K. Arkenbout, P. Carmeliet, V. Lindner, and H. Pannekoek
Plasminogen Activator Inhibitor 1 and Vitronectin Protect Against Stenosis in a Murine Carotid Artery Ligation Model
Arterioscler. Thromb. Vasc. Biol.,
December 1, 2002;
22(12):
1978 - 1983.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Kaneko, S. Fujii, A. Matsumoto, D. Goto, N. Ishimori, K. Watano, T. Furumoto, T. Sugawara, B. E. Sobel, and A. Kitabatake
Induction of Plasminogen Activator Inhibitor-1 in Endothelial Cells by Basic Fibroblast Growth Factor and Its Modulation by Fibric Acid
Arterioscler. Thromb. Vasc. Biol.,
May 1, 2002;
22(5):
855 - 860.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Luttun, F. Lupu, E. Storkebaum, M. F. Hoylaerts, L. Moons, J. Crawley, F. Bono, A. R. Poole, P. Tipping, J.-M. Herbert, et al.
Lack of Plasminogen Activator Inhibitor-1 Promotes Growth and Abnormal Matrix Remodeling of Advanced Atherosclerotic Plaques in Apolipoprotein E-Deficient Mice
Arterioscler. Thromb. Vasc. Biol.,
March 1, 2002;
22(3):
499 - 505.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Braun, B. L. Trigatti, M. J. Post, K. Sato, M. Simons, J. M. Edelberg, R. D. Rosenberg, M. Schrenzel, and M. Krieger
Loss of SR-BI Expression Leads to the Early Onset of Occlusive Atherosclerotic Coronary Artery Disease, Spontaneous Myocardial Infarctions, Severe Cardiac Dysfunction, and Premature Death in Apolipoprotein E-Deficient Mice
Circ. Res.,
February 22, 2002;
90(3):
270 - 276.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C.Y. Chan, D. A. Duszczyszyn, F. J. Castellino, and V. A. Ploplis
Accelerated Skin Wound Healing in Plasminogen Activator Inhibitor-1-Deficient Mice
Am. J. Pathol.,
November 1, 2001;
159(5):
1681 - 1688.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Westrick, P. F. Bodary, Z. Xu, Y.-C. Shen, G. J. Broze, and D. T. Eitzman
Deficiency of Tissue Factor Pathway Inhibitor Promotes Atherosclerosis and Thrombosis in Mice
Circulation,
June 26, 2001;
103(25):
3044 - 3046.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Zhu, P. M. Farrehi, and W. P. Fay
Plasminogen Activator Inhibitor Type 1 Enhances Neointima Formation After Oxidative Vascular Injury in Atherosclerosis-Prone Mice
Circulation,
June 26, 2001;
103(25):
3105 - 3110.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Braun, B. L. Trigatti, M. J. Post, K. Sato, M. Simons, J. M. Edelberg, R. D. Rosenberg, M. Schrenzel, and M. Krieger
Loss of SR-BI Expression Leads to the Early Onset of Occlusive Atherosclerotic Coronary Artery Disease, Spontaneous Myocardial Infarctions, Severe Cardiac Dysfunction, and Premature Death in Apolipoprotein E-Deficient Mice
Circ. Res.,
February 22, 2002;
90(3):
270 - 276.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. T. Eitzman, R. J. Westrick, X. Bi, S. L. Manning, J. E. Wilkinson, G. J. Broze, and D. Ginsburg
Lethal Perinatal Thrombosis in Mice Resulting From the Interaction of Tissue Factor Pathway Inhibitor Deficiency and Factor V Leiden
Circulation,
May 7, 2002;
105(18):
2139 - 2142.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|